Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. request reprint
    Matheson A, Goa K. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Paediatr Drugs. 2000;2:139-59 pubmed
    ..The low reactogenicity of DTaP3-CB is likely to make it well tolerated and therefore well accepted for the immunisation of infants, thereby enabling wider implementation of vaccination programmes. ..
  2. Hoy S, Keating G. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs. 2009;69:1077-105 pubmed publisher
    ..Thus, omega-3 EEC is a useful option both in secondary prevention post-MI and the treatment of hypertriglyceridaemia. ..
  3. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72:543-63 pubmed publisher
    ..In conclusion, indacaterol provides a valuable option for the maintenance treatment of adults with COPD. ..
  4. request reprint
    Figgitt D, McClellan K. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs. 2000;60:925-54 pubmed
    ..However, direct comparisons are required to assess the relative efficacy and tolerability of the different agents of this drug class. ..
  5. request reprint
    Frampton J, Wagstaff A. Alemtuzumab. Drugs. 2003;63:1229-43; discussion 1245-6 pubmed
    ..Anti-infective prophylaxis is mandatory. Cytopenias are transient, although red blood cell and platelet support may be required. ..
  6. request reprint
    Simpson D, Lyseng Williamson K. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs. 2006;66:2397-416 pubmed
    ..Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes. ..
  7. Scott L, Lyseng Williamson K. Spotlight on lenalidomide in relapsed or refractory multiple myeloma. BioDrugs. 2011;25:333-7 pubmed publisher
    ..Thus, combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma. ..
  8. request reprint
    Perry C, Balfour J. Fomivirsen. Drugs. 1999;57:375-80; discussion 381 pubmed
    ..These events were generally transient or reversible with topical steroid treatment. ..
  9. request reprint
    Dunn C, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 2000;60:203-37 pubmed
    ..Data are also accumulating to show dalteparin to be an effective and easily administered alternative to UFH in patients with CAD. ..

More Information

Publications222 found, 100 shown here

  1. request reprint
    Cheer S, Prakash A, Faulds D, Lamb H. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63:101-33 pubmed
    ..Thus, pantoprazole is a valuable alternative to other PPIs in the treatment of acid-related disorders. ..
  2. request reprint
    Keam S, Perry C. Prulifloxacin. Drugs. 2004;64:2221-34; discussion 2235-6 pubmed
    ..Prulifloxacin was generally well tolerated in clinical trials, with a similar tolerability profile to that of ciprofloxacin. ..
  3. Dhillon S, Keam S. DTaP-IPV/Hib vaccine (Pentacel). Paediatr Drugs. 2008;10:405-16 pubmed publisher
    ..The tolerability profile of DTaP-IPV/Hib vaccine was generally similar to that of separately administered DTaP, IPV, and Hib vaccines. ..
  4. Garnock Jones K, Keating G. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11:203-26 pubmed publisher
  5. Curran M, Robinson D. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69:1853-78 pubmed publisher
    ..Aprepitant was generally well tolerated. Aprepitant is a recommended option for the treatment of PONV, and when combined with a corticosteroid and 5-HT(3) receptor antagonist is a recommended regimen for the treatment of CINV. ..
  6. Dhillon S. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type. Drugs Aging. 2011;28:927-30 pubmed publisher
  7. Duggan S. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs. 2012;72:565-84 pubmed publisher
    ..Further studies evaluating the effects of pitavastatin on clinical endpoints, such as cardiovascular morbidity and mortality, are required to confirm the longer-term benefits of pitavastatin. ..
  8. request reprint
    Anderson V, Perry C, Robinson D. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs. 2006;6:417-32 pubmed
    ..Thus, ramipril, in addition to lifestyle interventions, should be considered an important therapy in the prevention of CV outcomes in high-risk patients. ..
  9. request reprint
    Murdoch D, Plosker G. Anidulafungin. Drugs. 2004;64:2249-58; discussion 2259-60 pubmed
    ..In the largest clinical trial to date, the most common treatment-related adverse events were phlebitis/thrombophlebitis, headache, nausea, vomiting and pyrexia. ..
  10. request reprint
    Keam S, Plosker G. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67:457-74 pubmed
    ..Thus, the introduction of rupatadine extends the range of oral agents available for the treatment of allergic disorders, including allergic rhinitis and CIU. ..
  11. request reprint
    Baldwin C, Keating G. Rotigotine transdermal patch: in restless legs syndrome. CNS Drugs. 2008;22:797-806 pubmed
    ..e. intensification of RLS symptoms) with rotigotine, although further evaluations are required to ascertain if continuous dopaminergic stimulation has the effect of limiting or preventing augmentation. ..
  12. Garnock Jones K. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. Drugs. 2012;72:361-73 pubmed publisher
    ..Azithromycin 1.5% ophthalmic solution was well tolerated in patients with bacterial or trachomatous conjunctivitis. Most events were of mild to moderate severity. ..
  13. request reprint
    Perry C, Barman Balfour J, Lamb H. Gatifloxacin. Drugs. 1999;58:683-96; discussion 697-8 pubmed
    ..The drug was reported to be well tolerated. Gatifloxacin does not appear to cause phototoxic effects. ..
  14. request reprint
    Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000;59:301-21 pubmed
    ..In those with excessive nasal congestion the combination of fexofenadine plus pseudoephedrine may be useful. In clinical trials fexofenadine is not associated with adverse cardiac or cognitive/psychomotor effects. ..
  15. request reprint
    Cvetkovic R, Scott L. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005-24 pubmed
    ..01). Dexrazoxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patient population. ..
  16. request reprint
    Lyseng Williamson K, Simpson D. Budesonide/Formoterol pressurized metered-dose inhaler. Drugs. 2008;68:1855-64 pubmed
    ..Its overall adverse event profile is consistent with the known tolerability profiles of long-acting [beta]2-adrenoceptor agonist and inhaled corticosteroid therapy, and is similar to that shown with placebo. ..
  17. Dhillon S. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs. 2009;69:2005-24 pubmed publisher
    ..Overall, considering the large unmet need for therapeutic options in patients with digital ulcers, bosentan extends the treatment options available to patients with systemic sclerosis-associated digital ulcers. ..
  18. Yang L, Scott L. Palonosetron: in the prevention of nausea and vomiting. Drugs. 2009;69:2257-78 pubmed publisher
    ..Intravenous palonosetron is a useful alternative to currently recommended agents in PONV prevention. ..
  19. request reprint
    Balfour J, Plosker G. Rosiglitazone. Drugs. 1999;57:921-30; discussion 931-2 pubmed
    ..There is no evidence to date that rosiglitazone shares the hepatotoxicity of troglitazone. ..
  20. request reprint
    Hurst M, Spencer C. Ebastine: an update of its use in allergic disorders. Drugs. 2000;59:981-1006 pubmed
    ..Ebastine does not appear to be associated with any significant cardiac adverse events. Ebastine is a useful treatment option for patients with allergic rhinitis or chronic idiopathic urticaria. ..
  21. request reprint
    Frampton J, Easthope S. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4:709-25 pubmed
    ..Repeated injections are necessary to maintain a long-term effect; however, this technique clearly represents an attractive option for individuals who wish to avoid a more major procedure. ..
  22. McCormack P, Joura E. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010;70:2449-74 pubmed publisher
  23. Keating G. Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents. CNS Drugs. 2011;25:333-42 pubmed publisher
    ..The vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial and the longer-term extension study. ..
  24. request reprint
    Oldfield V, Perry C. Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs. 2006;20:197-9 pubmed
    ..Thus, rasburicase is a useful option for the prophylaxis or treatment of anticancer therapy-induced hyperuricemia in both adult and pediatric patients. ..
  25. Moen M. Indacaterol: in chronic obstructive pulmonary disease. Drugs. 2010;70:2269-80 pubmed publisher
    ..Indacaterol was generally well tolerated by adults with moderate to severe COPD. ..
  26. request reprint
    Ormrod D, Holm K, Goa K, Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging. 1999;15:389-416 pubmed
    ..In the meantime there is sufficient evidence to justify consideration of epirubicin for inclusion in first-line therapies for patients with early or metastatic breast cancer. ..
  27. request reprint
    Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325-50 pubmed
    ..Thus mometasone furoate is suitable for the control of mild to severe persistent asthma in adults or adolescents. ..
  28. request reprint
    Cheer S, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501-20 pubmed
    ..In the meantime, TSI represents a valuable option for suppressive antipseudomonal therapy in patients with cystic fibrosis. ..
  29. Curran M. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs. 2012;14:51-60 pubmed publisher
    ..Everolimus was generally well tolerated in patients with SEGA associated with TSC; most drug-related adverse reactions were mild to moderate in severity. ..
  30. Duggan S, Scott L. Intravenous paracetamol (acetaminophen). Drugs. 2009;69:101-13 pubmed publisher
    ..Additionally, adverse reactions emerging from the use of the intravenous formulation of paracetamol are extremely rare (<1/10 000). [table: see text]. ..
  31. Dhillon S. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). BioDrugs. 2010;24:299-302 pubmed publisher
  32. McKeage K, Deeks E. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11:217-22 pubmed publisher
    ..Anti-inflammatory dose doxycycline 40 mg was generally well tolerated in clinical trials, with most adverse events being of mild to moderate intensity. ..
  33. request reprint
    Curran M, Perry C. Spotlight on amisulpride in schizophrenia. CNS Drugs. 2002;16:207-11 pubmed
    ..Amisulpride is a first-line treatment option in the management of schizophrenia in the acute phase and for the maintenance of treatment response. ..
  34. request reprint
    Hair P, Scott L. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66:973-96 pubmed
    ..Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU. ..
  35. Deeks E. Icatibant. Drugs. 2010;70:73-81 pubmed publisher
  36. request reprint
    McNeely W, Goa K. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. 1998;56:667-90 pubmed
    ..Nevertheless, in appropriately selected patients, PUVA 5-methoxypsoralen therapy may be recommended as an alternative first-line systemic treatment option for the management of vitiligo or psoriasis. ..
  37. Carter N, Curran M. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011;71:1591-622 pubmed publisher
    ..In the US, LAIV is indicated for the active immunization of healthy subjects aged 2-49 years against influenza disease caused by virus subtypes A and type B contained in the vaccine. ..
  38. request reprint
    McClellan K, Plosker G. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58:143-57 pubmed
    ..The role of trimetazidine in other coronary conditions has yet to be clearly established. ..
  39. request reprint
    McCormack P, Keam S. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs. 2009;11:75-88 pubmed
    ..Therefore, rotavirus vaccine RIX4414 offers a highly effective control strategy for reducing the burden of RVGE in infants. ..
  40. Plosker G, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26:893-915 pubmed publisher
  41. Hoy S, Keating G. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71:1481-501 pubmed publisher
  42. request reprint
    Balfour J, Goa K. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997;54:273-98 pubmed
    ..Further studies are required to determine whether it offers any advantages over other agents in these settings and to determine the optimum dosage for preventing RINV. ..
  43. Duggan S, Plosker G. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs. 2009;69:115-22 pubmed publisher
    ..fig: see text] ..
  44. Carter N, Keam S. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70:355-76 pubmed publisher
  45. Curran M, Leroux Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs. 2010;70:1519-43 pubmed publisher
    ..In conclusion, Fluarix is an important means of decreasing the impact of seasonal influenza viruses on adults and the elderly. ..
  46. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs. 2011;71:1209-31 pubmed publisher
  47. Plosker G. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics. 2011;29:989-1009 pubmed publisher
  48. Duggan S. Fidaxomicin: in Clostridium difficile infection. Drugs. 2011;71:2445-56 pubmed publisher
    ..Fidaxomicin was generally well tolerated in patients with C. difficile infection, with a tolerability profile generally similar to that of vancomycin. ..
  49. request reprint
    Hvizdos K, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs. 2000;60:1141-78 pubmed
    ..The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup. ..
  50. request reprint
    Wagstaff A, Frampton J, Croom K. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs. 2003;63:1101-20 pubmed
  51. request reprint
    Siddiqui M, Plosker G. Rasagiline. Drugs Aging. 2005;22:83-91; discussion 93-4 pubmed
    ..Adverse events with rasagiline were generally similar in frequency to those seen in placebo or entacapone recipients. ..
  52. request reprint
    Keating G, Scott L. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs. 2007;67:793-804 pubmed
    ..Preliminary results suggest that zoledronic acid is a cost-effective option in Paget's disease of bone. Thus, zoledronic acid is an important first-line treatment for Paget's disease of bone. ..
  53. Frampton J, Perry C. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs. 2008;68:2683-707 pubmed publisher
    ..Thus, intermittent ibandronate extends the range of pharmacological therapies for the treatment and prevention of postmenopausal osteoporosis. ..
  54. request reprint
    Scott L, Spencer C. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521-49 pubmed
    ..Miglitol may prove particularly beneficial in elderly patients and those with hepatic impairment or mild to moderate renal impairment, in whom other oral antidiabetic agents are contraindicated or need to be used with caution. ..
  55. request reprint
    Perry C, Ibbotson T. Biapenem. Drugs. 2002;62:2221-34; discussion 2235 pubmed
    ..Biapenem is generally well tolerated. The most common adverse events in clinical trials were skin eruptions/rashes, nausea and diarrhoea. ..
  56. Frampton J, Lyseng Williamson K. Degarelix. Drugs. 2009;69:1967-76 pubmed publisher
    ..Degarelix treatment for 1 year was generally well tolerated; the adverse events reported were mostly related to subcutaneous drug administration (i.e. injection-site reactions) and hormonal androgen deprivation (e.g. hot flushes). ..
  57. Hoy S, Scott L, Keating G. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24:227-44 pubmed publisher
    ..Intramuscular paliperidone palmitate 39-234 mg was generally well tolerated in adult patients with schizophrenia. ..
  58. Croxtall J, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70:2259-67 pubmed publisher
    ..In general, combination therapy with trastuzumab and chemotherapy was relatively well tolerated in patients with metastatic gastric cancer with no reports of new or unexpected adverse events. ..
  59. request reprint
    Hurst M, Lamb H. Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59:653-80 pubmed
    ..Meropenem has an important role in the empirical treatment of serious infections in adults and children in ICUs. ..
  60. request reprint
    Curran M, Perry C. Amisulpride: a review of its use in the management of schizophrenia. Drugs. 2001;61:2123-50 pubmed
    ..Amisulpride is a first-line treatment option in the management of schizophrenia in the acute phase and for the maintenance of treatment response. ..
  61. request reprint
    McCormack P, Wagstaff A. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs. 2006;66:931-8 pubmed
    ..The allergy vaccine was generally well tolerated. Local reactions, mainly injection-site redness and swelling, were more common than systemic reactions. There were no serious adverse events. ..
  62. McKeage K, Keam S. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26:883-92 pubmed publisher
    ..Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity. ..
  63. Lyseng Williamson K. Oral bepotastine: in allergic disorders. Drugs. 2010;70:1579-91 pubmed publisher
    ..Bepotastine was generally well tolerated in adult and paediatric patients with allergic conditions. ..
  64. request reprint
    Perry C, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-43 pubmed
  65. request reprint
    Keating G, Scott L. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs. 2004;64:2347-77 pubmed
    ..Thus, moxifloxacin is an important option in the treatment of bacterial infections. ..
  66. Hoy S, McKeage K. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma. Drugs. 2010;70:1819-29 pubmed publisher
    ..Adverse events were often managed with dose modifications. ..
  67. request reprint
    Wilde M, Wagstaff A. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-53 pubmed
    ..Longer term and comparative trials with other active therapies are required to confirm these promising results. ..
  68. request reprint
    Coukell A, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging. 1998;12:149-68 pubmed
    ..It is an effective treatment for Paget's disease and is the treatment of choice where oral bisphosphonates are not an option. ..
  69. request reprint
    McClellan K, Jarvis B. Desloratadine. Drugs. 2001;61:789-96; discussion 797 pubmed
    ..Sleep and daytime performance also improved. Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU. ..
  70. request reprint
    Dando T, Wiseman L. Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer. Drugs Aging. 2004;21:949-62 pubmed
    ..In the meantime, clodronate is a well established bisphosphonate which has shown beneficial effects in the prevention of bone metastases and on survival in patients with primary breast cancer. ..
  71. request reprint
    Anderson V, Curran M. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67:1947-67 pubmed
    ..parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths. ..
  72. Dhillon S, Weber J. Saxagliptin. Drugs. 2009;69:2103-14 pubmed publisher
    ..Saxagliptin therapy was not associated with an increased risk of cardiovascular events according to pooled data from eight clinical trials. Saxagliptin generally had a weight-neutral effect. ..
  73. Frampton J. Prucalopride. Drugs. 2009;69:2463-76 pubmed publisher
    ..Moreover, prucalopride at dosages up to 20 mg/day (10-fold higher than the recommended therapeutic dosage) had no clinically relevant effects on cardiovascular parameters in healthy volunteers. ..
  74. Dhillon S. Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain. Clin Drug Investig. 2010;30:711-38 pubmed publisher
  75. Scott L. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults. BioDrugs. 2010;24:387-406 pubmed publisher
  76. Deeks E, Perry C. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs. 2010;70:2315-38 pubmed publisher
  77. Deeks E. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs. 2011;71:209-20 pubmed publisher
    ..Olmesartan medoxomil?+?amlodipine?+?HCTZ was generally well tolerated in the TRINITY study, with adverse events usually being mild or moderate in severity. ..
  78. Lyseng Williamson K, Yang L. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol. 2012;13:67-71 pubmed publisher
    ..Romidepsin had an acceptable tolerability profile, with the most common grade 3 or 4 adverse events considered at least possibly related to romidepsin being hematologic or asthenic in nature. ..
  79. request reprint
    Lamb H, Figgitt D, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061-97 pubmed
    ..However, in VREF or unresponsive MRSA infections, where few proven treatment options exist, quinupristin/dalfopristin should be considered as a treatment of choice for these seriously ill patients. ..
  80. request reprint
    Dunn C, Goa K. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001;61:685-712 pubmed
    ..The effects of the drug on hip fracture incidence in elderly women with confirmed osteoporosis point to a particular role in older patients, or those with more advanced disease. ..
  81. request reprint
    Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging. 2001;18:441-72 pubmed
    ..These qualities make the drug suitable for first-line use in patients with COPD who require regular bronchodilator therapy to manage symptoms. ..
  82. request reprint
    Matheson A, Cheer S, Goa K. Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs. 2001;61:1211-29 pubmed
    ..The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension. ..
  83. Carter N, Scott L. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83-97 pubmed publisher
    ..6% was generally well tolerated in clinical trials, with most adverse events being mild in severity. The tolerability profile of besifloxacin ophthalmic suspension 0.6% was similar to that of moxifloxacin ophthalmic solution 0.5%. ..
  84. Garnock Jones K, Scott L. Fospropofol. Drugs. 2010;70:469-77 pubmed publisher
    ..Patients undergoing flexible bronchoscopy appeared to have a higher rate of sedation-related adverse events requiring airway assistance than did those undergoing colonoscopy or minor procedures. ..
  85. Dhillon S. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination. Drugs. 2010;70:1021-58 pubmed publisher
  86. McCormack P, Joura E. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. BioDrugs. 2011;25:339-43 pubmed publisher
  87. request reprint
    Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs. 2001;3:293-319 pubmed
    ..Although comparative studies with the other newer AEDs used in adjuntive therapy are required, topiramate is an important extension to the range of drugs that may be used to treat refractory epilepsy in children. ..
  88. McCormack P, Robinson D. Eslicarbazepine acetate. CNS Drugs. 2009;23:71-9 pubmed publisher
    ..Eslicarbazepine acetate was generally well tolerated in clinical trials. The majority of treatment-emergent adverse events were of mild to moderate severity and most occurred early in treatment. ..
  89. Garnock Jones K, Keating G. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69:2149-65 pubmed publisher
    ..Thus, the lidocaine 5% medicated plaster is a useful first-line option for the treatment of patients with PHN. ..
  90. Plosker G. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs. 2010;70:1843-55 pubmed publisher
    ..aeruginosa density in sputum in clinical trials. The tolerability profile of AZLI was generally similar to that of placebo in randomized controlled trials, with respiratory symptoms being the most frequently reported adverse events. ..
  91. Garnock Jones K. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11:57-72 pubmed publisher
    ..Dabigatran etexilate is a promising new option for the prevention of stroke and systemic embolism in patients with atrial fibrillation. ..
  92. Duggan S, Scott L. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation. Drugs. 2011;71:237-52 pubmed publisher
    ..Therefore, intravenous vernakalant provides an effective option for the management of recent-onset atrial fibrillation. ..